New York Times Interview:  A Dilemma for Governments: How to Pay for Million-Dollar Therapies

A wave of transformative but hugely expensive treatments is challenging the budgets of health systems in wealthy nations. Now countries with far fewer resources are wrestling with how to cover the therapies “Tay Salimullah, a Novartis executive, said the company works closely with governments and health plans considering whether to cover Zolgensma, in some cases allowing them to spread out their payments over time, like a mortgage, or offering a price cut if the treatment doesn’t work”. Full article HERE